China Universal Asset Management Co., Ltd. Larimar Therapeutics, Inc. Transaction History
China Universal Asset Management Co., Ltd.
- $1.05 Billion
- Q1 2025
A detailed history of China Universal Asset Management Co., Ltd. transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 12,799 shares of LRMR stock, worth $30,845. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,799
Previous 13,529
5.4%
Holding current value
$30,845
Previous $51,000
47.06%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding LRMR
# of Institutions
109Shares Held
64.5MCall Options Held
93.5KPut Options Held
68K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$51.2 Million1.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$14.6 Million0.27% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$13.4 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.78MShares$11.5 Million5.31% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$8.23 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $104M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...